Tamoxifen Citrate
Based on 259 publication(s) in Google Scholar
Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen Citrate activates autophagy and induces apoptosis. Tamoxifen Citrate can also be used to induce gene knockout in CreER transgenic mice.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.88%
- No. CAS: 54965-24-1
- Fòrmula: C32H37NO8
- Peso molecular:563.64
-
Almacenamiento:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Tamoxifen Citrate
More- Signal Transduct Target Ther. 2023 Feb 3;8(1):51. [Abstract]
- Cancer Cell. 2026 Feb 9;44(2):424-442.e14. [Abstract]
- Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]
- Science. 2026 Jul 2;393(6806):eaef0825. [Abstract]
- Science. 2026 Mar 19;391(6791):eadu7686. [Abstract]
- Cell. 2025 Sep 18;188(19):5194-5211.e16. [Abstract]
- Cell. 2025 May 29;188(11):3013-3029.e19. [Abstract]
- Cell. 2024 Sep 5;187(18):5064-5080.e14. [Abstract]
- Cell. 2022 Aug 4;185(16):3008-3024.e16. [Abstract]
- Cell Res. 2026 May 27. [Abstract]
- Cell Res. 2025 Feb;35(2):97-116. [Abstract]
- Immunity. 2024 Jan 9;57(1):106-123.e7. [Abstract]
- Immunity. 2022 Aug 9;55(8):1466-1482.e9. [Abstract]
- Immunity. 2020 Nov 17;53(5):1078-1094.e7. [Abstract]
- Cancer Commun (Lond). 2025 Oct 16. [Abstract]
- Cancer Commun (Lond). 2024 Nov;44(11):1350-1373. [Abstract]
- Gut. 2023 May;72(5):821-833. [Abstract]
- Cell Mol Immunol. 2026 May;23(5):471-490. [Abstract]
- Cell Mol Immunol. 2025 Oct 20. [Abstract]
- Cell Mol Immunol. 2025 Feb;22(2):134-149. [Abstract]
- Cell Mol Immunol. 2024 Oct;21(10):1131-1144. [Abstract]
- Nat Cell Biol. 2024 Dec;26(12):2099-2114. [Abstract]
- Cancer Res. 2024 Nov 15;84(22):3728-3742. [Abstract]
- Sci Bull. 2025 Sep 29:S2095-9273(25)00984-3. [Abstract]
- Nat Neurosci. 2025 Jul;28(7):1404-1417. [Abstract]
- Bone Res. 2024 Sep 6;12(1):53. [Abstract]
- Autophagy. 2026 May 31:1-22. [Abstract]
- Autophagy. 2025 Dec;21(12):3123-3141. [Abstract]
- Nat Commun. 2025 Apr 30;16(1):4047. [Abstract]
- Nat Commun. 2025 Jan 30;16(1):1175. [Abstract]
- Nat Commun. 2024 Dec 30;15(1):10838. [Abstract]
- Nat Commun. 2024 Nov 12;15(1):9770. [Abstract]
- Nat Commun. 2024 Oct 29;15(1):9337. [Abstract]
- Nat Commun. 2024 Sep 6;15(1):7791. [Abstract]
- Circ Res. 2025 Jan 17;136(2):e1-e19. [Abstract]
- J Adv Res. 2025 Jul 12:S2090-1232(25)00545-4. [Abstract]
- J Adv Res. 2025 Jul:73:501-515. [Abstract]
- J Adv Res. 2022 Nov:41:63-75. [Abstract]
- Neuron. 2026 Mar 16:S0896-6273(26)00137-6. [Abstract]
- Sci Immunol. 2025 Sep 5;10(111):eadq0457. [Abstract]
- Sci Immunol. 2025 Jul 11;10(109):eadu7962. [Abstract]
- Redox Biol. 2022 Nov:57:102509. [Abstract]
- Nucleic Acids Res. 2022 Oct 14;50(18):10230-10248. [Abstract]
- Theranostics. 2026 Feb 4;16(8):4452-4470. [Abstract]
- Theranostics. 2024 Aug 1;14(11):4499-4518. [Abstract]
- Theranostics. 2021 Sep 21;11(19):9623-9651. [Abstract]
- Theranostics. 2020 Sep 11;10(24):11159-11177. [Abstract]
- Theranostics. 2020 Aug 29;10(24):10874-10891. [Abstract]
- Acta Pharm Sin B. 2026 May 12.
- Biomark Res. 2025 May 7;13(1):70. [Abstract]
- J Clin Invest. 2026 Apr 2;136(12):e196112. [Abstract]
- J Clin Invest. 2026 Mar 2;136(5):e196905. [Abstract]
- J Clin Invest. 2026 Jan 2;136(1):e195506. [Abstract]
- J Clin Invest. 2025 Oct 16:e188822. [Abstract]
- J Clin Invest. 2025 Jun 2;135(11):e184158. [Abstract]
- J Clin Invest. 2025 Jan 16;135(2):e178198. [Abstract]
- J Exp Clin Cancer Res. 2024 Jun 20;43(1):173. [Abstract]
- Adv Sci (Weinh). 2026 May 20:e18564. [Abstract]
- Adv Sci (Weinh). 2026 Feb;13(10):e17825. [Abstract]
- Adv Sci (Weinh). 2025 Nov 10:e10991. [Abstract]
- Adv Sci (Weinh). 2025 Oct 14:e15374. [Abstract]
- Adv Sci (Weinh). 2025 Aug 4:e03972. [Abstract]
- Adv Sci (Weinh). 2025 Aug 11:e02535. [Abstract]
- Adv Sci (Weinh). 2024 Aug;11(29):e2401676. [Abstract]
- Cell Rep Med. 2025 Apr 15;6(4):102053. [Abstract]
- Sci Adv. 2026 Jun 12;12(24):eaed2731. [Abstract]
- Sci Adv. 2024 Jul 5;10(27):eadm7373. [Abstract]
- Sci Adv. 2024 Jul 19;10(29):eadp5239. [Abstract]
- Sci Adv. 2024 Feb 2;10(5):eadj7813. [Abstract]
- Sci Adv. 2023 Sep;9(35):eadg7125. [Abstract]
- Cell Death Differ. 2026 Jan 28. [Abstract]
- Cell Death Differ. 2025 Nov 26. [Abstract]
- Cell Death Differ. 2025 Jul 19. [Abstract]
- Biomaterials. 2025 Jun:317:123062. [Abstract]
- Research (Wash D C). 2025 Feb 19:8:0619. [Abstract]
- Cardiovasc Res. 2026 Mar 24:cvag069. [Abstract]
- Chem Eng J. 2026 Mar 19.
- Cardiovasc Res. 2025 Nov 11:cvaf219. [Abstract]
- Cardiovasc Res. 2025 Aug 7:cvaf136. [Abstract]
- Cardiovasc Res. 2025 May 6;121(4):568-584. [Abstract]
- Cardiovasc Res. 2024 Sep 21;120(11):1312-1326. [Abstract]
- Cell Death Dis. 2026 Feb 9. [Abstract]
- Cell Death Dis. 2025 Nov 30. [Abstract]
- Cell Death Dis. 2025 Mar 25;16(1):201. [Abstract]
- Cell Death Dis. 2023 Dec 5;14(12):796. [Abstract]
- Cell Death Dis. 2021 Oct 26;12(11):1003. [Abstract]
- Cancer Lett. 2024 May 28:590:216839. [Abstract]
- Cancer Lett. 2024 Mar 1:584:216609. [Abstract]
- Int J Biol Sci. 2025 Mar 19;21(6):2462-2475. [Abstract]
- Cell Commun Signal. 2019 May 23;17(1):50. [Abstract]
- J Neuroinflammation. 2025 Dec 8. [Abstract]
- J Neuroinflammation. 2025 Oct 31;22(1):253. [Abstract]
- J Neuroinflammation. 2024 Nov 14;21(1):295. [Abstract]
- Phytomedicine. 2026 Jan:150:157748. [Abstract]
- Phytomedicine. 2024 May:127:155461. [Abstract]
- Arch Toxicol. 2025 May 3. [Abstract]
- J Hazard Mater. 2023 Oct 15:460:132489. [Abstract]
- eGastroenterology. 2026 Mar 31;4(1):e100348. [Abstract]
- Mol Psychiatry. 2025 Aug 6. [Abstract]
- Sci China Life Sci. 2025 Jul;68(7):2010-2027. [Abstract]
- Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2203779120. [Abstract]
- Proc Natl Acad Sci U S A. 2022 Oct 4;119(40):e2204716119. [Abstract]
- Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):e2024258118. [Abstract]
- Dev Cell. 2025 Sep 3:S1534-5807(25)00530-1. [Abstract]
- Dev Cell. 2024 Aug 19;59(16):2085-2100.e9. [Abstract]
- Oncogene. 2025 Sep 16:10.1038/s41388-025-03571-1. [Abstract]
- NPJ Breast Cancer. 2025 Jul 17;11(1):73. [Abstract]
- NPJ Breast Cancer. 2022 Mar 10;8(1):31. [Abstract]
- Mater Des. 2025 Oct.
- Clin Transl Med. 2020 Jan;10(1):137-150. [Abstract]
- Br J Cancer. 2025 Dec 9. [Abstract]
- ACS Appl Mater Interfaces. 2025 Aug 27;17(34):48029-48043. [Abstract]
- Stem Cell Res Ther. 2025 Mar 5;16(1):111. [Abstract]
- Br J Cancer. 2022 Sep;127(5):927-936. [Abstract]
- Cell Rep. 2026 May 28;45(6):117471. [Abstract]
- Cell Rep. 2025 Dec 11;44(12):116678. [Abstract]
- Cell Rep. 2025 Nov 25;44(11):116563. [Abstract]
- Cell Rep. 2025 Aug 5;44(8):116112. [Abstract]
- Cell Rep. 2025 Jan 2;44(1):115126. [Abstract]
- Cell Rep. 2024 May 10;43(5):114226. [Abstract]
- Cell Rep. 2024 Feb 17;43(2):113804. [Abstract]
- Cell Rep. 2024 Feb 15;43(2):113786. [Abstract]
- Cell Rep. 2023 Sep 30;42(10):113202. [Abstract]
- Cell Rep. 2023 Sep 19;42(10):113158. [Abstract]
- Cell Prolif. 2025 Dec 30:e70158. [Abstract]
- Cell Prolif. 2024 Nov;57(11):e13700. [Abstract]
- Cell Prolif. 2023 Jul;56(7):e13406. [Abstract]
- Cell Prolif. 2021 Jan;54(1):e12953. [Abstract]
- Transl Psychiatry. 2025 Aug 15;15(1):285. [Abstract]
- Br J Pharmacol. 2024 Oct;181(20):3908-3925. [Abstract]
- Brain Behav Immun. 2024 Jan:115:705-717. [Abstract]
- J Med Chem. 2020 Oct 8;63(19):11085-11099. [Abstract]
- Atherosclerosis. 2025 Dec:411:120558. [Abstract]
- Cancer Cell Int. 2024 Dec 27;24(1):433. [Abstract]
- Front Immunol. 2024 Mar 27:15:1374943. [Abstract]
- J Invest Dermatol. 2023 Dec;143(12):2366-2377.e7. [Abstract]
- Front Immunol. 2022 Mar 10;13:805420. [Abstract]
- Pharmaceutics. 2022 Jan 12;14(1):176. [Abstract]
- J Ethnopharmacol. 2026 May 10:362:121345. [Abstract]
- Neurosci Bull. 2026 Mar 22. [Abstract]
- Neurosci Bull. 2025 May 2. [Abstract]
- J Ethnopharmacol. 2024 Jan 10;318(Pt B):117075. [Abstract]
- CNS Neurosci Ther. 2026 Feb;32(2):e70756. [Abstract]
- Biochem Pharmacol. 2026 Jun 12;251(Pt 2):118163. [Abstract]
- Biochem Pharmacol. 2026 May:247:117796. [Abstract]
- Biochem Pharmacol. 2025 Oct:240:117107. [Abstract]
- J Bone Miner Res. 2025 Jun 3;40(6):799-812. [Abstract]
- Biochem Pharmacol. 2024 Jul:225:116256. [Abstract]
- Cell Mol Life Sci. 2024 Jan 22;81(1):49. [Abstract]
- Cell Mol Life Sci. 2023 Mar 18;80(4):100. [Abstract]
- Biochem Pharmacol. 2021 Jun:188:114583. [Abstract]
- Life Sci. 2026 Mar 15:389:124236. [Abstract]
- Breast Cancer Res. 2024 Mar 11;26(1):44. [Abstract]
- Transl Res. 2023 Jul:257:54-65. [Abstract]
- Cells. 2026 Feb 23;15(4):383. [Abstract]
- Biomacromolecules. 2015 Sep 14;16(9):2701-14. [Abstract]
- Pharmaceuticals (Basel). 2026 May 19;19(5):795. [Abstract]
- Pharmaceuticals (Basel). 2026 Apr 24;19(5):667. [Abstract]
- Int Immunopharmacol. 2026 Jun 20:185:117023. [Abstract]
- Int Immunopharmacol. 2025 Sep 6:165:115494. [Abstract]
- Int J Mol Sci. 2025 Jul 9;26(14):6593. [Abstract]
- Int Immunopharmacol. 2024 Oct 31;143(Pt 3):113485. [Abstract]
- Int J Mol Sci. 2022 Feb 28;23(5):2664. [Abstract]
- Glia. 2026 Jun;74(6):e70159. [Abstract]
- Glia. 2025 Jul 28. [Abstract]
- Glia. 2024 Feb;72(2):396-410. [Abstract]
- mBio. 2023 Apr 25;14(2):e0054923. [Abstract]
- J Clin Endocrinol Metab. 2021 Apr 23;106(5):1410-1426. [Abstract]
- Chem Biol Interact. 2024 Feb 1:389:110865. [Abstract]
- Chem Biol Interact. 2022 Sep 25:365:110091. [Abstract]
- Bioorg Chem. 2026 Jun 18:180:110129. [Abstract]
- Exp Gerontol. 2026 Jan:213:112994. [Abstract]
- Mol Med Rep. 2026 Jun;33(6):183. [Abstract]
- PLoS Pathog. 2025 Sep 10;21(9):e1013464. [Abstract]
- Sci Rep. 2025 Jul 1;15(1):22255. [Abstract]
- PLoS Pathog. 2025 Apr 10;21(4):e1013052. [Abstract]
- Exp Neurol. 2026 Sep:403:115819. [Abstract]
- Neoplasia. 2025 Mar:61:101125. [Abstract]
- Cancers (Basel). 2023 Aug 11;15(16):4066. [Abstract]
- Cancers (Basel). 2021 Feb 3;13(4):599. [Abstract]
- Neuropharmacology. 2026 Nov 1:298:111043. [Abstract]
- Med Oncol. 2025 Jul 21;42(8):358. [Abstract]
- Mol Cell Biochem. 2025 Apr;480(4):2423-2435. [Abstract]
- Cell Signal. 2024 May:117:111080. [Abstract]
- J Cell Mol Med. 2024 Jan;28(1):e18007. [Abstract]
- J Cell Mol Med. 2020 Jan;24(2):1599-1613. [Abstract]
- Aquat Toxicol. 2026 Jun:295:107814. [Abstract]
- Biomedicines. 2026 Jun 15;14(6):1344. [Abstract]
- iScience. 2025 Sep 10;28(10):113536. [Abstract]
- J Neurosci. 2024 Jul 24;44(30):e2192232024. [Abstract]
- Prog Neuropsychopharmacol Biol Psychiatry. 2026 Jun 20:147:111763. [Abstract]
- Appl Biol Chem. 2026 Jun 24;69(1):36.
- Neurobiol Stress. 2026 Mar 21:42:100804. [Abstract]
- J Biol Chem. 2026 Jun;302(6):111480. [Abstract]
- J Biol Chem. 2025 Jan;301(1):108070. [Abstract]
- RNA Biol. 2021 Apr;18(4):468-480. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 May 28. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 18. [Abstract]
- JOR Spine. 2025 Nov 4;8(4):e70133. [Abstract]
- Viruses. 2024 Apr 20;16(4):643. [Abstract]
- Biotechnol J. 2026 May;21(5):e70236. [Abstract]
- Cardiovasc Drugs Ther. 2026 Mar 13. [Abstract]
- Int J Biochem Cell Biol. 2024 Jul:172:106585. [Abstract]
- Cardiovasc Drugs Ther. 2024 Apr;38(2):237-252. [Abstract]
- Bioorg Med Chem. 2023 Mar 15:82:117235. [Abstract]
- J Pharm Biomed Anal. 2021 Feb 20:195:113870. [Abstract]
- Breast Cancer Res Treat. 2023 Dec;202(3):595-606. [Abstract]
- Chin J Integr Med. 2026 Jan 15. [Abstract]
- Oral Dis. 2025 Jul;31(7):2229-2242. [Abstract]
- J Steroid Biochem Mol Biol. 2024 Nov:244:106599. [Abstract]
- Hear Res. 2026 Aug:478:109691. [Abstract]
- Front Genet. 2022 Sep 20:13:992444. [Abstract]
- Biochim Biophys Acta Gen Subj. 2023 Sep;1867(9):130413. [Abstract]
- Toxicol Res (Camb). 2022 Jul 22;11(4):673-682. [Abstract]
- PLoS One. 2025 Jul 28;20(7):e0328698. [Abstract]
- Biochem Biophys Res Commun. 2026 Aug 20:827:154022. [Abstract]
- Biochem Biophys Res Commun. 2025 Sep 1:777:152327. [Abstract]
- Biochem Biophys Res Commun. 2024 Dec 10:737:150916. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 15:1237:124100. [Abstract]
- Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868. [Abstract]
- Pharmacol Biochem Behav. 2025 Dec:257:174114. [Abstract]
- Oncol Lett. 2025 Feb 21;29(4):194. [Abstract]
- Am J Transl Res. 2018 Jul 15;10(7):2184-2194. [Abstract]
- Res Sq. 2026 Jun 2.
- bioRxiv. 2026 May 21.
- Res Sq. 2026 Feb 2.
- Res Sq. 2026 Feb 23.
- SSRN. 2025 Nov 6.
- SSRN. 2025 Sep 30.
- SSRN. 2025 Oct 13.
- bioRxiv. 2025 Oct 6.
- bioRxiv. 2025 Oct 14:2025.10.12.681919. [Abstract]
- bioRxiv. 2025 Oct 7:2025.10.06.680702. [Abstract]
- Cureus. 2025 Oct 20;17(10):e94996. [Abstract]
- bioRxiv. 2025 Jun 17.
- bioRxiv. 2025 February 23.
- Res Sq. 2024 Oct 16.
- Res Sq. 2024 Aug 26.
- Patent. US20240217988A1.
- bioRxiv. 2024 August 04.
- Res Sq. 2024 Jun 04.
- Heliyon. 2024 Jun 14;10(12):e33104. [Abstract]
- SSRN. 2024 Mar 26.
- SSRN. 2024 Jan 10.
- Journal of the Institute of Science and Technology. 2023 Mar 3, 13(4), 2997-3006.
- bioRxiv. 2023 Dec 18.
- bioRxiv. 2023 Aug 22.
- Research Square Preprint. 2023 Aug 7.
- bioRxiv. 2023 Jun 22.
- bioRxiv. 2023 Mar 15:2023.03.14.532677. [Abstract]
- bioRxiv. 2023 Feb 7.
- bioRxiv. 2023 Jan 31.
- Universität Basel. 2022.
- Research Square Preprint. 2022 May.
- Research Square Preprint. 2022 May.
- Research Square Preprint. 2021 Oct.
- Res Sq. 2020 Dec 31:rs.3.rs-100914. [Abstract]
- bioRxiv. 2020 Mar.
- Chemosphere. 2020 Jan:239:124705. [Abstract]
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
IHC
-
WB
Actividad biológica
|
Estrogen receptor |
HSP90 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | ED50 |
7 μg/mL
Compound: TAM
|
Effective dose for reduction in cell growth of human skin cancer A431 cell line
Effective dose for reduction in cell growth of human skin cancer A431 cell line
|
[PMID: 15509181] |
| DU-145 | IC50 |
11.2 μM
Compound: Tam citrate
|
Anticancer activity against human DU-145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Anticancer activity against human DU-145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 30772606] |
| DU-145 | IC50 |
15.25 μM
Compound: Tamoxifen citrate
|
Cytotoxicity against human DU145 cells after 18 hrs by MTT assay
Cytotoxicity against human DU145 cells after 18 hrs by MTT assay
|
[PMID: 19932024] |
| HEK293 | IC50 |
27.3 μM
Compound: Tam citrate
|
Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 30772606] |
| HEK293 | IC50 |
30 μM
Compound: Tamoxifen citrate
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 29352645] |
| Ishikawa | IC50 |
12.5 μM
Compound: Tamoxifen citrate
|
Cytotoxicity against human Ishikawa cells after 18 hrs by MTT assay
Cytotoxicity against human Ishikawa cells after 18 hrs by MTT assay
|
[PMID: 19932024] |
| KB | ED50 |
9 μg/mL
Compound: TAM
|
Dose required for reduction in cell growth of human nasopharyngeal carcinoma KB cell line
Dose required for reduction in cell growth of human nasopharyngeal carcinoma KB cell line
|
[PMID: 15509181] |
| KB | ED50 |
9 μg/mL
Compound: TAM
|
Dose required for reduction in cell growth of vincristine-resistant human nasopharyngeal carcinoma KB cell line
Dose required for reduction in cell growth of vincristine-resistant human nasopharyngeal carcinoma KB cell line
|
[PMID: 15509181] |
| LNCaP | ED50 |
6 μg/mL
Compound: TAM
|
Dose required for reduction in cell growth of human AR-dependent prostate cancer LN-CaP cell line
Dose required for reduction in cell growth of human AR-dependent prostate cancer LN-CaP cell line
|
[PMID: 15509181] |
| MCF7 | ED50 |
5 μg/mL
Compound: TAM
|
Dose required for reduction in cell growth of estrogen positive human breast cancer MCF-7 cell line (ER+)
Dose required for reduction in cell growth of estrogen positive human breast cancer MCF-7 cell line (ER+)
|
[PMID: 15509181] |
| MCF7 | IC50 |
0.796 μM
Compound: Tamoxifen citrate
|
Inhibition of 17-beta estradiol-induced cell proliferation in human MCF7 cells incubated for 6 days by acid red-52 staining based assay
Inhibition of 17-beta estradiol-induced cell proliferation in human MCF7 cells incubated for 6 days by acid red-52 staining based assay
|
[PMID: 28882502] |
| MCF7 | IC50 |
10.2 μM
Compound: Tamoxifen citrate
|
Cytotoxicity against human MCF7 cells after 18 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 18 hrs by MTT assay
|
[PMID: 19932024] |
| MCF7 | IC50 |
13.7 μM
Compound: Tamoxifen citrate
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 29352645] |
| MCF7 | IC50 |
6.2 μM
Compound: Tam citrate
|
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 30772606] |
| MCF7 | IC50 |
9.53 μM
Compound: Tamoxifen citrate
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 32947093] |
| MDA-MB-231 | ED50 |
8 μg/mL
Compound: TAM
|
Dose required for reduction in cell growth of estrogen negative human breast cancer MDA-MB-231 cell line (ER-)
Dose required for reduction in cell growth of estrogen negative human breast cancer MDA-MB-231 cell line (ER-)
|
[PMID: 15509181] |
| MDA-MB-231 | IC50 |
10.71 μM
Compound: Tamoxifen citrate
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 32947093] |
| MDA-MB-231 | IC50 |
12.3 μM
Compound: Tamoxifen citrate
|
Cytotoxicity against human MDA-MB-231 cells after 18 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 18 hrs by MTT assay
|
[PMID: 19932024] |
| MDA-MB-231 | IC50 |
12.8 μM
Compound: Tam citrate
|
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 30772606] |
| MDA-MB-231 | IC50 |
17.9 μM
Compound: Tamoxifen citrate
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 29352645] |
| PC-3 | ED50 |
10 μg/mL
Compound: TAM
|
Dose required for reduction in cell growth of human prostate cancer PC-3 cell line
Dose required for reduction in cell growth of human prostate cancer PC-3 cell line
|
[PMID: 15509181] |
| PC-3 | IC50 |
11.7 μM
Compound: Tam citrate
|
Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 30772606] |
| SK-BR-3 | ED50 |
5 μg/mL
Compound: TAM
|
Dose required for reduction in cell growth of estrogen negative human breast cancer SK-BR-3 cell line(ER-)
Dose required for reduction in cell growth of estrogen negative human breast cancer SK-BR-3 cell line(ER-)
|
[PMID: 15509181] |
| SW-620 | ED50 |
4 μg/mL
Compound: TAM
|
Dose required for reduction in cell growth of human colon cancer SW620 cell line
Dose required for reduction in cell growth of human colon cancer SW620 cell line
|
[PMID: 15509181] |
| Vero C1008 | CC50 |
37.96 μM
Compound: Tamoxifen Citrate
|
CC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells
CC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells
|
10.1101/2020.03.25.008482 |
| Vero C1008 | CC50 |
37.96 μM
Compound: Tamoxifen Citrate
|
CC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells
CC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells
|
10.1101/2020.03.25.008482 |
| Vero C1008 | IC50 |
34.12 μM
Compound: Tamoxifen Citrate
|
IC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells
IC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells
|
10.1101/2020.03.25.008482 |
| Vero C1008 | IC50 |
8.98 μM
Compound: Tamoxifen Citrate
|
IC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells
IC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells
|
10.1101/2020.03.25.008482 |
| ZR-75-1 | ED50 |
5 μg/mL
Compound: TAM
|
Dose required for reduction in cell growth of estrogen positive human breast cancer ZR-75-1 cell line (ER+)
Dose required for reduction in cell growth of estrogen positive human breast cancer ZR-75-1 cell line (ER+)
|
[PMID: 15509181] |
Tamoxifen Citrate (ICI 46474) shows strong inhibition of MCF-7 cells (EC50=1.41 μM) and to a lesser extent the T47D cells (EC50=2.5 μM) but does not affect the MDA-MB-231 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Administration: 75 mg/kg • i.p. • once daily for 5 consecutive days
(2) Administration methods: Common methods include intraperitoneal injection, and it can also be administered by oral gavage or subcutaneous injection. When performing multiple intraperitoneal injections, the injection sites should be alternated.
(3) Dosage: The dosage is 50-120 mg/kg, with 3-5 intraperitoneal injections, usually for 5 consecutive days. The dosage for pregnant mice and aged mice (over 6 months old) should be appropriately reduced. Tamoxifen can affect fetal development and parturition. For pregnant mice, the induction time should preferably be selected in the late pregnancy stage, and progesterone should be injected simultaneously to reduce the probability of miscarriage.
(4) Mice: Mice at 4-6 weeks old may be more sensitive (it is more effective in young mice than in old mice).
(5) Potential toxicity: Prolonged high-level Cre activity can cause potential toxicity. In addition, if an important functional gene is knocked out or using Homozygous Mice, it may also lead to the death of mice. Therefore, close observation should be carried out within one or two weeks after induction. If the mice show abnormalities, the causes need to be analyzed in a timely manner and the experimental plan should be adjusted.
(6) Control: Control group mice should be injected with an equal amount of the corn oil solution of Tamoxifen (using Tamoxifen in a genetic background without Cre recombinase) to rule out the influence of Tamoxifen itself.
(7) Detection window: The time window between Tamoxifen administration and the start of the experiment should be large enough, at least 7 days, to ensure that the Cre recombinase enters the nucleus and functions.
(8) Separate caging: Animals treated with Tamoxifen should be caged separately from untreated animals to avoid cross - contamination caused by behaviors such as animals licking the oily Tamoxifen suspension, grooming their fur, or coprophagy.
Administration: 45 mg/kg • i.p. • once daily for 7 days
(2) At the end of the experiment, the animals were euthanized by cervical dislocation under mild ether anesthesia. The blood samples were collected in heparinized centrifuge tubes and centrifuged to obtain serum. The abdomen was opened, and the liver was immediately dissected and removed. It was washed with ice-cold isotonic saline and blotted between two filter papers. The liver was wrapped in aluminum foil and stored at -80°C. A 10% (w/v) liver homogenate was prepared in ice-cold 0.1 M potassium phosphate buffer (pH 7.5) using an ultrasonicator.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 54965-24-1
-
Appearance Solid
-
Peso molecular 563.64
-
Fòrmula C32H37NO8
-
Color White to off-white
-
SMILES
CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3.O=C(CC(C(O)=O)(O)CC(O)=O)O
-
Synonyms
ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
Publications (259)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
2023 Feb 3;8(1):51. PMID: 36732502 -
Cancer Cell
Single-cell screens identify ADAM12 as a fibroblast checkpoint impeding anti-tumor immunity. [Abstract]2026 Feb 9;44(2):424-442.e14. PMID: 41544628 -
Cancer Cell
2024 Nov 11;42(11):1955-1969.e7. PMID: 39532065
Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]
Peripheral blood chimerism (%Cd45.2) in mice engrafted with WT (Cd45.1) and Flt3Frt-ITD (Cd45.2) cells following treatment with Tamoxifen (4 mg/mouse; p.o.) (red) or control (black).
Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]
Flt3Frt-ITD (red), Dnmt3aLox-R878H-Flt3Frt-ITD (orange), and Npm1Frt-c-Flt3Frt-ITD (green) bone marrow was transplanted into lethally irradiated hosts. Kaplan-Meier survival plot following TAM (4 mg/mouse; p.o.).
Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]
Bone marrow H&E from either control mice or after 7 days of TAM (4 mg/mouse; p.o.).
Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]
Immunohistochemical staining on bone marrow for Ki67 (left) and phopsho-ERK1/2 (right) for untreated (top) and 7-day TAM (4 mg/mouse; p.o.) treated (bottom) Npm1Lox-C-Flt3GL-ITD mice.
-
Science
2026 Jul 2;393(6806):eaef0825. PMID: 42391361 -
Science
Commensal-driven serotonin production modulates in vivo delivery of synthetic and viral vectors. [Abstract]2026 Mar 19;391(6791):eadu7686. PMID: 41855345 -
Cell
Procr+ chondroprogenitors sense mechanical stimuli to govern articular cartilage maintenance and regeneration. [Abstract]2025 Sep 18;188(19):5194-5211.e16. PMID: 40695281 -
Cell
2025 May 29;188(11):3013-3029.e19. PMID: 40252640 -
Cell
2024 Sep 5;187(18):5064-5080.e14. PMID: 39089254 -
Cell
2022 Aug 4;185(16):3008-3024.e16. PMID: 35870449 -
Cell Res
2026 May 27. PMID: 42191977 -
Cell Res
Nonenzymatic lysine D-lactylation induced by glyoxalase II substrate SLG dampens inflammatory immune responses. [Abstract]2025 Feb;35(2):97-116. PMID: 39757301 -
Immunity
2024 Jan 9;57(1):106-123.e7. PMID: 38159573 -
Immunity
Microglia-derived PDGFB promotes neuronal potassium currents to suppress basal sympathetic tonicity and limit hypertension. [Abstract]2022 Aug 9;55(8):1466-1482.e9. PMID: 35863346 -
Immunity
Affinity-Restricted Memory B Cells Dominate Recall Responses to Heterologous Flaviviruses. [Abstract]2020 Nov 17;53(5):1078-1094.e7. PMID: 33010224
Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Immunity. 2020 Nov 17;53(5):1078-1094.e7. [Abstract]
Frequency of TdTomato-labelled cells in TdT-Jchain mice treated with Tamoxifen (mice; 50 mg/kg; oral gavage; for two consecutive days) 14 and 15 days after WNV vaccination was analyzed by flow cytometry 13 days later (28 days after WNV vaccination) and compared to week 1 labeling.
-
Cancer Commun (Lond)
RNA m1A methyltransferase TRMT61A promotes colorectal tumorigenesis by enhancing ONECUT2 mRNA stability and is a potential therapeutic target. [Abstract]2025 Oct 16. PMID: 41103012 -
Cancer Commun (Lond)
Yap methylation-induced FGL1 expression suppresses anti-tumor immunity and promotes tumor progression in KRAS-driven lung adenocarcinoma. [Abstract]2024 Nov;44(11):1350-1373. PMID: 39340215 -
Gut
IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis. [Abstract]2023 May;72(5):821-833. PMID: 35613844 -
Cell Mol Immunol
SPT6 maintains epidermal homeostasis by inhibiting an NF-κB-positive feedback loop to prevent excessive inflammation. [Abstract]2026 May;23(5):471-490. PMID: 41922599 -
Cell Mol Immunol
An animal model of NLRC4-associated autoinflammation and infantile enterocolitis reveals novel therapeutic strategies. [Abstract]2025 Oct 20. PMID: 41116055 -
Cell Mol Immunol
Demyelination-derived lysophosphatidylserine promotes microglial dysfunction and neuropathology in a mouse model of Alzheimer's disease. [Abstract]2025 Feb;22(2):134-149. PMID: 39741193 -
Cell Mol Immunol
2024 Oct;21(10):1131-1144. PMID: 39030423 -
Nat Cell Biol
Spermidine mediates acetylhypusination of RIPK1 to suppress diabetes onset and progression. [Abstract]2024 Dec;26(12):2099-2114. PMID: 39511379
Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Dec;26(12):2099-2114. [Abstract]
Tamoxifen (2 mg/day; i.p.; for 5 consecutive days) can effectively induce the removal of NAT1 in various tissues, including muscle, white adipose tissue, pancreas, and liver, in adult Nat1fl/fl;UBCcreERT2/+ mice and in Nat1fl/fl;UBCcreERT2/+;Ripk1D138N/D138N mice carrying a RIPK1 allele with an inactivation mutation.
-
Cancer Res
YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer. [Abstract]2024 Nov 15;84(22):3728-3742. PMID: 39137404
Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Nov 15;84(22):3728-3742. [Abstract]
Schematic image of selective YAP1 depletion model on Cd248-CreERT2; Yap1flox/flox mice by using Tamoxifen (120 mg/kg/day; i.p. for 5 d).
-
Sci Bull
Nuclear receptor ESRRA promotes ERα-positive breast cancer through dual action on super enhancers and promoters to regulate gene transcriptional programs. [Abstract]2025 Sep 29:S2095-9273(25)00984-3. PMID: 41111053 -
Nat Neurosci
GABA-dependent microglial elimination of inhibitory synapses underlies neuronal hyperexcitability in epilepsy. [Abstract]2025 Jul;28(7):1404-1417. PMID: 40425792 -
Bone Res
Osteopontin deficiency promotes cartilaginous endplate degeneration by enhancing the NF-κB signaling to recruit macrophages and activate the NLRP3 inflammasome. [Abstract]2024 Sep 6;12(1):53. PMID: 39242551 -
Autophagy
Mechanical stress-mediated ferritinophagy aggravates cartilage endplate degeneration via a PIEZO1-NCOA4-ZBP1 axis. [Abstract]2026 May 31:1-22. PMID: 42153663 -
Autophagy
2025 Dec;21(12):3123-3141. PMID: 40963239 -
Nat Commun
Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy. [Abstract]2025 Apr 30;16(1):4047. PMID: 40307212 -
Nat Commun
2025 Jan 30;16(1):1175. PMID: 39885146 -
Nat Commun
Mammalian SLC39A13 promotes ER/Golgi iron transport and iron homeostasis in multiple compartments. [Abstract]2024 Dec 30;15(1):10838. PMID: 39738060 -
Nat Commun
Mechanics-activated fibroblasts promote pulmonary group 2 innate lymphoid cell plasticity propelling silicosis progression. [Abstract]2024 Nov 12;15(1):9770. PMID: 39532893 -
Nat Commun
Alternations in inflammatory macrophage niche drive phenotypic and functional plasticity of Kupffer cells. [Abstract]2024 Oct 29;15(1):9337. PMID: 39472435 -
Nat Commun
Astrocyte-derived clusterin disrupts glial physiology to obstruct remyelination in mouse models of demyelinating diseases. [Abstract]2024 Sep 6;15(1):7791. PMID: 39242637 -
Circ Res
2025 Jan 17;136(2):e1-e19. PMID: 39655444 -
J Adv Res
SIRT7 facilitates ferroptosis resistance of melanocytes via activating the SMAD3-ATF3-GPX4 signaling pathway in vitiligo. [Abstract]2025 Jul 12:S2090-1232(25)00545-4. PMID: 40659088 -
J Adv Res
GDF11 protects against mitochondrial-dysfunction-dependent NLRP3 inflammasome activation to attenuate osteoarthritis. [Abstract]2025 Jul:73:501-515. PMID: 39103049 -
J Adv Res
Mechanical overloading induces GPX4-regulated chondrocyte ferroptosis in osteoarthritis via Piezo1 channel facilitated calcium influx. [Abstract]2022 Nov:41:63-75. PMID: 36328754 -
Neuron
Oligodendrocyte-encoded lactate dehydrogenase A couples glycolysis to remyelination via protein lactylation. [Abstract]2026 Mar 16:S0896-6273(26)00137-6. PMID: 41844160 -
Sci Immunol
DDX55 safeguards naïve T cell homeostasis by suppressing activation-promoting transposable elements. [Abstract]2025 Sep 5;10(111):eadq0457. PMID: 40911696 -
Sci Immunol
2025 Jul 11;10(109):eadu7962. PMID: 40644510 -
Redox Biol
Inhibition of ferroptosis and iron accumulation alleviates pulmonary fibrosis in a bleomycin model. [Abstract]2022 Nov:57:102509. PMID: 36302319
Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Nov:57:102509. [Abstract]
Expression of TFRC in primary fibroblasts from TFRCflox/flox and TFRC−/− mice was assessed by western blot after 5 days of Tamoxifen intraperitoneal injection and 7 days of waiting.
-
Nucleic Acids Res
Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer. [Abstract]2022 Oct 14;50(18):10230-10248. PMID: 36124682 -
Theranostics
2026 Feb 4;16(8):4452-4470. PMID: 41695487 -
Theranostics
Rbm24/Notch1 signaling regulates adult neurogenesis in the subventricular zone and mediates Parkinson-associated olfactory dysfunction. [Abstract]2024 Aug 1;14(11):4499-4518. PMID: 39113792 -
Theranostics
A novel lncRNA linc-AhRA negatively regulates innate antiviral response in murine microglia upon neurotropic herpesvirus infection. [Abstract]2021 Sep 21;11(19):9623-9651. PMID: 34646390 -
Theranostics
Rbm24 modulates adult skeletal muscle regeneration via regulation of alternative splicing. [Abstract]2020 Sep 11;10(24):11159-11177. PMID: 33042276 -
Theranostics
Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development. [Abstract]2020 Aug 29;10(24):10874-10891. PMID: 33042259
Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Aug 29;10(24):10874-10891. [Abstract]
Representative fields, intracellular TG contents and secreted TG of female C57BL/6 mice hepatocytes treated with C29, Tamoxifen (20 μM; 36 h), Toremifene and 4-OHT. LDs were labeled with Nile Red (red).
Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Aug 29;10(24):10874-10891. [Abstract]
Representative images of liver tissue (top), sections stained with Oil Red O (bottom) and liver TG levels from Ad-ERRα or Ad-Ctrl-injected female mice treated with TMX (100 mg/kg; p.o. for 5 days).
-
-
Biomark Res
PAQR5 drives the malignant progression and shapes the immunosuppressive microenvironment of hepatocellular carcinoma by activating the NF-κB signaling. [Abstract]2025 May 7;13(1):70. PMID: 40336138 -
J Clin Invest
Aging-dependent microglial heterogeneity worsens outcomes in models of traumatic brain injury. [Abstract]2026 Apr 2;136(12):e196112. PMID: 41926211 -
J Clin Invest
Ectopic B lymphocyte follicles exacerbate ischemic brain damage via MIF-CD74/CXCR4 and interferon signaling. [Abstract]2026 Mar 2;136(5):e196905. PMID: 41766668 -
J Clin Invest
Astrocyte-intrinsic signaling of chitinase-like protein CHI3L1 drives inflammation and amplifies demyelination in neuromyelitis optica. [Abstract]2026 Jan 2;136(1):e195506. PMID: 41480772 -
J Clin Invest
Excessive collagen type VII mediates pleural fibrosis via increasing extracellular matrix stiffness. [Abstract]2025 Oct 16:e188822. PMID: 41100460 -
J Clin Invest
2025 Jun 2;135(11):e184158. PMID: 40454481 -
J Clin Invest
Inhibition of aortic CX3CR1+ macrophages mitigates thoracic aortic aneurysm progression in Marfan syndrome in mice. [Abstract]2025 Jan 16;135(2):e178198. PMID: 39817456 -
J Exp Clin Cancer Res
The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer. [Abstract]2024 Jun 20;43(1):173. PMID: 38898487 -
Adv Sci (Weinh)
CD4+ Tregs Drive Post-Ischemic Sprouting Angiogenesis via Endothelial YY1/MAML1 Reactivation. [Abstract]2026 May 20:e18564. PMID: 42159401 -
Adv Sci (Weinh)
AXL Promotes Ischemic Myelin Repair Through Alleviating Myelin Debris Deposition and Lipid Droplets Accumulation. [Abstract]2026 Feb;13(10):e17825. PMID: 41524160 -
Adv Sci (Weinh)
Piezo1 Upregulation in Monocyte-Derived Macrophages Impairs Post-Myocardial Infarction Cardiac Repair via Defective Efferocytosis and Enhanced Ferroptosis. [Abstract]2025 Nov 10:e10991. PMID: 41214880 -
Adv Sci (Weinh)
2025 Oct 14:e15374. PMID: 41085070 -
Adv Sci (Weinh)
2025 Aug 4:e03972. PMID: 40755418 -
Adv Sci (Weinh)
2025 Aug 11:e02535. PMID: 40787892 -
Adv Sci (Weinh)
Targeting Rab7-Rilp Mediated Microlipophagy Alleviates Lipid Toxicity in Diabetic Cardiomyopathy. [Abstract]2024 Aug;11(29):e2401676. PMID: 38837607 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 15;6(4):102053. PMID: 40187357 -
Sci Adv
Quantitative prediction of siRNA complexation by ionizable drugs enables their codelivery in nanoparticles. [Abstract]2026 Jun 12;12(24):eaed2731. PMID: 42284421 -
Sci Adv
ZBTB21 suppresses CRE-mediated transcription to impair synaptic function in Down syndrome. [Abstract]2024 Jul 5;10(27):eadm7373. PMID: 38959316 -
Sci Adv
Beta2 adrenergic receptor-mediated abnormal myelopoiesis drives neuroinflammation in aged patients with traumatic brain injury. [Abstract]2024 Jul 19;10(29):eadp5239. PMID: 39028822 -
Sci Adv
Microglial Ffar4 deficiency promotes cognitive impairment in the context of metabolic syndrome. [Abstract]2024 Feb 2;10(5):eadj7813. PMID: 38306420 -
Sci Adv
TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. [Abstract]2023 Sep;9(35):eadg7125. PMID: 37647391 -
Cell Death Differ
TUFT1 stabilizes TGF-β receptor II protein and facilitates activation of hepatic stellate cells into metastasis-promoting myofibroblasts. [Abstract]2026 Jan 28. PMID: 41593321 -
Cell Death Differ
HDAC3 activates endothelial NLRP3 inflammasome and promotes atherosclerosis via inhibiting the acetylation of specificity protein 1. [Abstract]2025 Nov 26. PMID: 41299088 -
Cell Death Differ
FMRP regulation of STAT3-MYC signaling is critical for adult hippocampal neurogenesis and cognitive flexibility. [Abstract]2025 Jul 19. PMID: 40683950 -
Biomaterials
Black phosphorus nanosheets activate tumor immunity of glioblastoma by modulating the expression of the immunosuppressive molecule PD-L1. [Abstract]2025 Jun:317:123062. PMID: 39736218 -
Research (Wash D C)
Regulating Integrin β1 to Restore Gonadotropin-Releasing Hormone-Tanycyte Unit Function in Polycystic Ovary Syndrome-Related Hypothalamic Dysregulation. [Abstract]2025 Feb 19:8:0619. PMID: 39975575 -
Cardiovasc Res
METTL14 inhibits atherogenesis by epigenetically activating PPAR-α/γ transcription and fatty acid oxidation in VSMCs. [Abstract]2026 Mar 24:cvag069. PMID: 41873711 -
-
Cardiovasc Res
RBM24 regulates phenotypic switching of smooth muscle cell in vascular remodeling by stabilizing JAK2 mRNA. [Abstract]2025 Nov 11:cvaf219. PMID: 41216933 -
Cardiovasc Res
YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in VSMCs. [Abstract]2025 Aug 7:cvaf136. PMID: 40795179 -
Cardiovasc Res
METTL3-catalyzed m6A methylation facilitates the contribution of vascular smooth muscle cells to atherosclerosis. [Abstract]2025 May 6;121(4):568-584. PMID: 39977233 -
Cardiovasc Res
Cardiomyocyte βII spectrin plays a critical role in maintaining cardiac function by regulating mitochondrial respiratory function. [Abstract]2024 Sep 21;120(11):1312-1326. PMID: 38832923 -
Cell Death Dis
Endothelial IRE1 signaling maintains blood-brain barrier integrity and limits neuroinflammation after traumatic brain injury. [Abstract]2026 Feb 9. PMID: 41663365 -
Cell Death Dis
RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion. [Abstract]2025 Nov 30. PMID: 41318657 -
Cell Death Dis
ATP6AP1 promotes cell proliferation and tamoxifen resistance in luminal breast cancer by inducing autophagy. [Abstract]2025 Mar 25;16(1):201. PMID: 40133274 -
Cell Death Dis
Deletion of Mettl3 in mesenchymal stem cells promotes acute myeloid leukemia resistance to chemotherapy. [Abstract]2023 Dec 5;14(12):796. PMID: 38052820 -
Cell Death Dis
Cardiac-specific CGI-58 deficiency activates the ER stress pathway to promote heart failure in mice. [Abstract]2021 Oct 26;12(11):1003. PMID: 34702801 -
Cancer Lett
JAML promotes the antitumor role of tumor-resident CD8+ T cells by facilitating their innate-like function in human lung cancer. [Abstract]2024 May 28:590:216839. PMID: 38570084 -
Cancer Lett
DHCR7 promotes lymph node metastasis in cervical cancer through cholesterol reprogramming-mediated activation of the KANK4/PI3K/AKT axis and VEGF-C secretion. [Abstract]2024 Mar 1:584:216609. PMID: 38211648 -
Int J Biol Sci
The SGK3/GSK3β/β-catenin signaling promotes breast cancer stemness and confers resistance to alpelisib therapy. [Abstract]2025 Mar 19;21(6):2462-2475. PMID: 40303291 -
Cell Commun Signal
Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer. [Abstract]2019 May 23;17(1):50. PMID: 31122254
Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2019 May 23;17(1):50. [Abstract]
Tamoxifen inhibits the growth and metastasis of prostate tumors in vivo. Western blot analysis of the indicated proteins in prostate primary tumors tissues.
-
J Neuroinflammation
Hyperglycemia impairs microglia responding to retinal vasculopathy via enhanced norepinephrine-ADRB2 signaling. [Abstract]2025 Dec 8. PMID: 41361454 -
J Neuroinflammation
Microglial NLRC5 drives lysosomal dysfunction to disrupt autophagic flux and promote post-stroke neuroinflammation. [Abstract]2025 Oct 31;22(1):253. PMID: 41174779 -
J Neuroinflammation
Prolactin deficiency drives diabetes-associated cognitive dysfunction by inducing microglia-mediated synaptic loss. [Abstract]2024 Nov 14;21(1):295. PMID: 39543619 -
Phytomedicine
Tongmai Huazheng mixture attenuates adenomyosis by inducing ferroptosis through suppression of the JAK2/STAT3 signaling pathway. [Abstract]2026 Jan:150:157748. PMID: 41477983 -
Phytomedicine
Paris polyphylla ethanol extract and polyphyllin I ameliorate adenomyosis by inhibiting epithelial-mesenchymal transition. [Abstract]2024 May:127:155461. PMID: 38452697 -
Arch Toxicol
Fibroblast EGFR signaling mediates ricin toxin-induced acute lung injury via EGR1/CXCL1 axis. [Abstract]2025 May 3. PMID: 40317338 -
J Hazard Mater
Fibroblast-derived CXCL14 aggravates crystalline silica-induced pulmonary fibrosis by mediating polarization and recruitment of interstitial macrophages. [Abstract]2023 Oct 15:460:132489. PMID: 37688871 -
eGastroenterology
2026 Mar 31;4(1):e100348. PMID: 41948149 -
Mol Psychiatry
Anterior insular cortex regulates depression-like and ASD-like behaviors via the differential contribution of two subsets of microglia. [Abstract]2025 Aug 6. PMID: 40770435 -
Sci China Life Sci
Downregulation of METTL3 enhances TRADD-mediated apoptosis in inflammatory bowel disease. [Abstract]2025 Jul;68(7):2010-2027. PMID: 40347213 -
Proc Natl Acad Sci U S A
Bone marrow-derived IGF-1 orchestrates maintenance and regeneration of the adult skeleton. [Abstract]2023 Jan 3;120(1):e2203779120. PMID: 36577075 -
Proc Natl Acad Sci U S A
2022 Oct 4;119(40):e2204716119. PMID: 36161929 -
Proc Natl Acad Sci U S A
DDX11 loss causes replication stress and pharmacologically exploitable DNA repair defects. [Abstract]2021 Apr 27;118(17):e2024258118. PMID: 33879618 -
Dev Cell
A pathological role of O-GlcNAcylation-driven TR11B production and function in lung adenocarcinoma. [Abstract]2025 Sep 3:S1534-5807(25)00530-1. PMID: 40930100 -
Dev Cell
FGD5 in basal cells induces CXCL14 secretion that initiates a feedback loop to promote murine mammary epithelial growth and differentiation. [Abstract]2024 Aug 19;59(16):2085-2100.e9. PMID: 38821057 -
Oncogene
2025 Sep 16:10.1038/s41388-025-03571-1. PMID: 40957950 -
NPJ Breast Cancer
2025 Jul 17;11(1):73. PMID: 40675988 -
NPJ Breast Cancer
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. [Abstract]2022 Mar 10;8(1):31. PMID: 35273179 -
-
Clin Transl Med
2020 Jan;10(1):137-150. PMID: 32508033
Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2020 Jan;10(1):137-150. [Abstract]
Different transmission of MAPK8/FoxO signaling pathway in breast cancer cells (MCF-7, T47D, ZR-75, and MDA-MB-231) and liver cells (LO2) exposed to TAM (Tamoxifen).
-
Br J Cancer
Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer. [Abstract]2025 Dec 9. PMID: 41366063 -
ACS Appl Mater Interfaces
A Self-Delivering Oxygen Modulator for Breast Cancer Immunotherapy via Pyroptosis Induction and PD-L1 Degradation. [Abstract]2025 Aug 27;17(34):48029-48043. PMID: 40796528 -
Stem Cell Res Ther
Adipose-derived stem cells attenuate rheumatoid arthritis by restoring CX3CR1+ synovial lining macrophage barrier. [Abstract]2025 Mar 5;16(1):111. PMID: 40038808 -
Br J Cancer
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer. [Abstract]2022 Sep;127(5):927-936. PMID: 35618789 -
Cell Rep
2026 May 28;45(6):117471. PMID: 42213774 -
Cell Rep
Paracrine stimulation of brown adipose tissue vascularization by adipocyte O-GlcNAc signaling. [Abstract]2025 Dec 11;44(12):116678. PMID: 41385373 -
Cell Rep
The xCT/CD98 complex suppresses ferroptosis in pan-cancer via a non-canonical RACK1-mediated iron homeostasis pathway. [Abstract]2025 Nov 25;44(11):116563. PMID: 41252251 -
Cell Rep
2025 Aug 5;44(8):116112. PMID: 40773347 -
Cell Rep
Maternal phthalates exposure promotes neural stem cell differentiation into phagocytic astrocytes and synapse engulfment via IRE1α/XBP1s pathway. [Abstract]2025 Jan 2;44(1):115126. PMID: 39752254 -
Cell Rep
Astrocyte-derived CHI3L1 signaling impairs neurogenesis and cognition in the demyelinated hippocampus. [Abstract]2024 May 10;43(5):114226. PMID: 38733586 -
Cell Rep
A microglial activation cascade across cortical regions underlies secondary mechanical hypersensitivity to amputation. [Abstract]2024 Feb 17;43(2):113804. PMID: 38368612 -
Cell Rep
RORα is required for expansion and memory maintenance of ILC1s via a lymph node-liver axis. [Abstract]2024 Feb 15;43(2):113786. PMID: 38363684 -
Cell Rep
CDKL5 deficiency in adult glutamatergic neurons alters synaptic activity and causes spontaneous seizures via TrkB signaling. [Abstract]2023 Sep 30;42(10):113202. PMID: 37777961 -
Cell Rep
2023 Sep 19;42(10):113158. PMID: 37733588 -
Cell Prolif
SOX30 Governs Synaptonemal Complex Assembly and Homologous Recombination in Male Meiosis. [Abstract]2025 Dec 30:e70158. PMID: 41467312 -
Cell Prolif
MCL restrained ROS/AKT/ASAH1 pathway to therapy tamoxifen resistance breast cancer by stabilizing NRF2. [Abstract]2024 Nov;57(11):e13700. PMID: 38924190 -
Cell Prolif
Type H vessel/platelet-derived growth factor receptor β+ perivascular cell disintegration is involved in vascular injury and bone loss in radiation-induced bone damage. [Abstract]2023 Jul;56(7):e13406. PMID: 36694343 -
Cell Prolif
Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. [Abstract]2021 Jan;54(1):e12953. PMID: 33211371 -
Transl Psychiatry
Microglia-mediated inflammation and synaptic pruning contribute to sleep deprivation-induced mania in a sex-specific manner. [Abstract]2025 Aug 15;15(1):285. PMID: 40817224 -
Br J Pharmacol
Microglial forkhead box O3a deficiency attenuates LPS-induced neuro-inflammation and depressive-like behaviour through regulating the expression of peroxisome proliferator-activated receptor-γ. [Abstract]2024 Oct;181(20):3908-3925. PMID: 38881194 -
Brain Behav Immun
2024 Jan:115:705-717. PMID: 37992789 -
J Med Chem
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. [Abstract]2020 Oct 8;63(19):11085-11099. PMID: 32886512 -
Atherosclerosis
Nicotine induces m6A-modified eNOS dysregulation to aggravate endothelial injury in male mice. [Abstract]2025 Dec:411:120558. PMID: 41192190 -
Cancer Cell Int
2024 Dec 27;24(1):433. PMID: 39731167 -
Front Immunol
Development of a customizable mouse backbone spectral flow cytometry panel to delineate immune cell populations in normal and tumor tissues. [Abstract]2024 Mar 27:15:1374943. PMID: 38605953 -
J Invest Dermatol
2023 Dec;143(12):2366-2377.e7. PMID: 37394057 -
Front Immunol
Analysis of Mononuclear Phagocytes Disclosed the Establishment Processes of Two Macrophage Subsets in the Adult Murine Kidney. [Abstract]2022 Mar 10;13:805420. PMID: 35359928 -
Pharmaceutics
Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets. [Abstract]2022 Jan 12;14(1):176. PMID: 35057070 -
J Ethnopharmacol
The modified Zuojin formula (SQQT) associates ILC2-linked JAK-2/STAT5/c-Myc cascade and gastric metaplasia regression. [Abstract]2026 May 10:362:121345. PMID: 41663001 -
Neurosci Bull
Neuronal and Glial YAP/TAZ in the Spinal Cord Contribute to the Development of Bone Cancer Pain in Mice. [Abstract]2026 Mar 22. PMID: 41866450 -
Neurosci Bull
Endothelial Cell Integrin α6 Regulates Vascular Remodeling Through the PI3K/Akt-eNOS-VEGFA Axis After Stroke. [Abstract]2025 May 2. PMID: 40316875 -
J Ethnopharmacol
Combining transcriptomics and network pharmacology to reveal the mechanism of zuojin capsule improving spasmolytic polypeptide-expressing metaplasia. [Abstract]2024 Jan 10;318(Pt B):117075. PMID: 37625606 -
CNS Neurosci Ther
SIX2-Mediated Microglial M2 Polarization and Exosomal miR-3470b Delivery Protect Dopaminergic Neurons in Parkinson's Disease. [Abstract]2026 Feb;32(2):e70756. PMID: 41700504 -
Biochem Pharmacol
Targeting neuropilin-1 attenuates 4-hydroxytamoxifen-induced stemness and sensitizes ERα-re-expressing TNBC to tamoxifen. [Abstract]2026 Jun 12;251(Pt 2):118163. PMID: 42285368 -
Biochem Pharmacol
Mutant NPM1-regulated estrogen signaling promotes leukemia cell survival by upregulating HGF and represents a therapeutic vulnerability. [Abstract]2026 May:247:117796. PMID: 41679667 -
Biochem Pharmacol
2025 Oct:240:117107. PMID: 40619010 -
J Bone Miner Res
Single cell RNA sequencing shows that cells expressing Sox9 postnatally populate most skeletal lineages in mouse bone. [Abstract]2025 Jun 3;40(6):799-812. PMID: 40143416 -
Biochem Pharmacol
MICAL-L2, as an estrogen-responsive gene, is involved in ER-positive breast cancer cell progression and tamoxifen sensitivity via the AKT/mTOR pathway. [Abstract]2024 Jul:225:116256. PMID: 38729448 -
Cell Mol Life Sci
Selenium-SelK-GPX4 axis protects nucleus pulposus cells against mechanical overloading-induced ferroptosis and attenuates senescence of intervertebral disc. [Abstract]2024 Jan 22;81(1):49. PMID: 38252317 -
Cell Mol Life Sci
Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer. [Abstract]2023 Mar 18;80(4):100. PMID: 36933062 -
Biochem Pharmacol
A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ERα mutants in breast cancer. [Abstract]2021 Jun:188:114583. PMID: 33915156 -
Life Sci
A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]2026 Mar 15:389:124236. PMID: 41611204 -
Breast Cancer Res
UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5. [Abstract]2024 Mar 11;26(1):44. PMID: 38468288 -
Transl Res
Dach1 deficiency drives alveolar epithelium apoptosis in pulmonary fibrosis via modulating C-Jun/Bim activity. [Abstract]2023 Jul:257:54-65. PMID: 36754276 -
Cells
A Comprehensive Adenoid Cystic Carcinoma-Derived Organoid Platform for Disease Modeling and Drug Screening Captures Interpatient Heterogeneity. [Abstract]2026 Feb 23;15(4):383. PMID: 41744826 -
Biomacromolecules
Noncovalent Surface Locking of Mesoporous Silica Nanoparticles for Exceptionally High Hydrophobic Drug Loading and Enhanced Colloidal Stability. [Abstract]2015 Sep 14;16(9):2701-14. PMID: 26200587 -
Pharmaceuticals (Basel)
Development and Application of an UPLC-MS/MS Method for Simultaneous Quantification of Abemaciclib and Tamoxifen with Their Active Metabolites in Rat Plasma: Application to a Pharmacokinetic Study. [Abstract]2026 May 19;19(5):795. PMID: 42198468 -
Pharmaceuticals (Basel)
Refined Jianpi Huayu Jiedu Decoction Attenuates TAM-Induced Spasmolytic Polypeptide-Expressing Metaplasia (SPEM) by Modulating LCN2-Associated Mitochondrial Dysfunction. [Abstract]2026 Apr 24;19(5):667. PMID: 42198341 -
Int Immunopharmacol
Hexokinase 2 deficiency protects against sepsis-associated lung injury via suppressing the NF-κB signaling pathway. [Abstract]2026 Jun 20:185:117023. PMID: 42322859 -
Int Immunopharmacol
The immunoregulator β-glucan produces antidepressant effects through microglia-mobilized astrocytic P2Y1R-BDNF signaling in the dentate gyrus. [Abstract]2025 Sep 6:165:115494. PMID: 40915186 -
Int J Mol Sci
HER2-Driven Breast Cancer: Role of the Chaperonin HSP90 in Modulating Response to Trastuzumab-Based Therapeutic Combinations. [Abstract]2025 Jul 9;26(14):6593. PMID: 40724844 -
Int Immunopharmacol
ATP citrate lyase ablation hampers exocrine regeneration via TLR4/NF-kappaB signaling after acute pancreatitis in mice. [Abstract]2024 Oct 31;143(Pt 3):113485. PMID: 39486178 -
Int J Mol Sci
Tamoxifen Exerts Anticancer Effects on Pituitary Adenoma Progression via Inducing Cell Apoptosis and Inhibiting Cell Migration. [Abstract]2022 Feb 28;23(5):2664. PMID: 35269804 -
Glia
Targeted Inhibition of MEGF10-Mediated Astrogliosis Reduces Glial Scar Formation and Promotes Neurofunction Recovery in Mice After Stroke. [Abstract]2026 Jun;74(6):e70159. PMID: 41999081 -
Glia
2025 Jul 28. PMID: 40719051 -
Glia
2024 Feb;72(2):396-410. PMID: 37909251 -
mBio
Genome-Wide CRISPR-Cas9 Screen Identifies SMCHD1 as a Restriction Factor for Herpesviruses. [Abstract]2023 Apr 25;14(2):e0054923. PMID: 37010434 -
J Clin Endocrinol Metab
2021 Apr 23;106(5):1410-1426. PMID: 33524147 -
Chem Biol Interact
Vitamin D inhibits tamoxifen-induced non-alcoholic fatty liver disease through a nonclassical estrogen receptor/liver X receptor pathway. [Abstract]2024 Feb 1:389:110865. PMID: 38191086 -
Chem Biol Interact
Fatostatin inhibits SREBP2-mediated cholesterol uptake via LDLR against selective estrogen receptor α modulator-induced hepatic lipid accumulation. [Abstract]2022 Sep 25:365:110091. PMID: 35944649 -
Bioorg Chem
A novel ERα-targeted hydrophobic tag degrader, overcomes tamoxifen resistance via unfolded protein response-induced apoptosis and homologous recombination repair inhibition in breast cancer. [Abstract]2026 Jun 18:180:110129. PMID: 42348942 -
Exp Gerontol
Hepcidin inhibits osteoclast differentiation to alleviate osteoporosis by modulating the p53/miR-34a/Trem2 axis. [Abstract]2026 Jan:213:112994. PMID: 41386388 -
Mol Med Rep
Mechanotransducer Piezo1 drives ventilator‑induced lung injury in lung epithelial cells via the calcineurin/NFATc3 pathway. [Abstract]2026 Jun;33(6):183. PMID: 42059278 -
PLoS Pathog
CK2 derived from brain microvascular endothelial cells induces astrocyte inflammatory response in Escherichia coli-induced meningitis. [Abstract]2025 Sep 10;21(9):e1013464. PMID: 40929057 -
Sci Rep
Impact of prenatal Di(2-ethylhexyl) phthalate exposure on pubertal development in female offspring rats: A focus on ERα-Mediated IGF-1/NKB crosstalk in the hypothalamus. [Abstract]2025 Jul 1;15(1):22255. PMID: 40595203 -
PLoS Pathog
Disrupting the OTUD4-USP7 deubiquitinase complex to suppress herpesvirus replication: a novel antiviral strategy. [Abstract]2025 Apr 10;21(4):e1013052. PMID: 40208866 -
Exp Neurol
Oligodendrocyte lineage cell-specific GPR17/Gelsolin signaling regulates remyelination and cognitive recovery after subarachnoid hemorrhage. [Abstract]2026 Sep:403:115819. PMID: 42107622 -
Neoplasia
SLC31A1 promotes chemoresistance through inducing CPT1A-mediated fatty acid oxidation in ER-positive breast cancer. [Abstract]2025 Mar:61:101125. PMID: 39904115 -
Cancers (Basel)
BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer. [Abstract]2023 Aug 11;15(16):4066. PMID: 37627092 -
Cancers (Basel)
Loss of cIAP1 in Endothelial Cells Limits Metastatic Extravasation through Tumor-Derived Lymphotoxin Alpha. [Abstract]2021 Feb 3;13(4):599. PMID: 33546280 -
Neuropharmacology
GPR139-mediated cholinergic circuit from the medial septum to the ventral hippocampal CA3 modulates cognitive impairment in Alzheimer's disease. [Abstract]2026 Nov 1:298:111043. PMID: 42218995 -
Med Oncol
Ursolic acid affects autophagy and apoptosis of breast cancer through PLK1 via AKT/mTOR signaling pathway. [Abstract]2025 Jul 21;42(8):358. PMID: 40691672 -
Mol Cell Biochem
Endothelium Piezo1 deletion alleviates experimental varicose veins by attenuating perivenous inflammation. [Abstract]2025 Apr;480(4):2423-2435. PMID: 39249600 -
Cell Signal
Rap1GAP exacerbates myocardial infarction by regulating the AMPK/SIRT1/NF-κB signaling pathway. [Abstract]2024 May:117:111080. PMID: 38320624 -
J Cell Mol Med
Microglial FoxO3a deficiency ameliorates ferroptosis-induced brain injury of intracerebral haemorrhage via regulating autophagy and heme oxygenase-1. [Abstract]2024 Jan;28(1):e18007. PMID: 37890842 -
J Cell Mol Med
Tamoxifen inhibits cell proliferation by impaired glucose metabolism in gallbladder cancer. [Abstract]2020 Jan;24(2):1599-1613. PMID: 31782270 -
Aquat Toxicol
Is acyl-CoA cholesterol acyltransferase 2 the enzyme responsible for the esterification of okadaic acid in bivalves?. [Abstract]2026 Jun:295:107814. PMID: 41935504 -
Biomedicines
Caveolin-1 Modulates Islet Amyloid Polypeptide Expression Through Interaction with TXNIP in Murine Pancreatic β-Cells. [Abstract]2026 Jun 15;14(6):1344. PMID: 42351772 -
iScience
2025 Sep 10;28(10):113536. PMID: 41069851 -
J Neurosci
2024 Jul 24;44(30):e2192232024. PMID: 38897723 -
Prog Neuropsychopharmacol Biol Psychiatry
Microglial HMGB2 mediates neuroinflammation and brain damage in Cx3cr1-creERT2 epileptic mice through astrocyte-derived CCL2. [Abstract]2026 Jun 20:147:111763. PMID: 42218973 -
-
Neurobiol Stress
Microglial SIRT6 confers protection against neuroinflammation-associated depression through NRF2-HO1 signaling. [Abstract]2026 Mar 21:42:100804. PMID: 41938092 -
J Biol Chem
Caveolin-1 deficiency improved glucose metabolism via modulation of β-cell autophagy in high-fat diet-fed mice. [Abstract]2026 Jun;302(6):111480. PMID: 42031171 -
J Biol Chem
Downregulation of the splicing regulator NSRP1 confers resistance to CDK4/6 inhibitors via activation of interferon signaling in breast cancer. [Abstract]2025 Jan;301(1):108070. PMID: 39667501 -
RNA Biol
Rbm24 regulates inner-ear-specific alternative splicing and is essential for maintaining auditory and motor coordination. [Abstract]2021 Apr;18(4):468-480. PMID: 32887533 -
Naunyn Schmiedebergs Arch Pharmacol
ML385 increases ferroptosis via inhibiting Nrf2/HO-1 pathway to enhances the sensitivity of MCF-7 TAMR to tamoxifen. [Abstract]2025 May 28. PMID: 40425765 -
Naunyn Schmiedebergs Arch Pharmacol
Overexpression of KIF2C amplifies tamoxifen resistance and lung metastasis of breast cancer through PLK1/C-Myc pathway. [Abstract]2025 Mar 18. PMID: 40100379 -
JOR Spine
PIEZO1-Primary Cilia Axis Mediates Compressive Stress-Induced Growth Plate Degeneration and Ossification in Adolescent Idiopathic Scoliosis. [Abstract]2025 Nov 4;8(4):e70133. PMID: 41194970 -
Viruses
Autophagy Deregulation in HIV-1-Infected Cells Increases Extracellular Vesicle Release and Contributes to TLR3 Activation. [Abstract]2024 Apr 20;16(4):643. PMID: 38675983 -
Biotechnol J
Engineering a Membrane-Anchored CreER Recombinase With Reduced Basal Activity for In Vitro Recombination. [Abstract]2026 May;21(5):e70236. PMID: 42116754 -
Cardiovasc Drugs Ther
E3 Ubiquitin Ligase UBR5 Aggravates Cardiac Hypertrophy Via Inhibiting Nrf2/HO-1 Pathway. [Abstract]2026 Mar 13. PMID: 41824182 -
Int J Biochem Cell Biol
Tamoxifen upregulates the peroxisomal β-oxidation enzyme Enoyl CoA hydratase and 3-hydroxyacyl CoA hydratase ameliorating hepatic lipid accumulation in mice. [Abstract]2024 Jul:172:106585. PMID: 38734232 -
Cardiovasc Drugs Ther
2024 Apr;38(2):237-252. PMID: 36350487 -
Bioorg Med Chem
A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway. [Abstract]2023 Mar 15:82:117235. PMID: 36905762 -
J Pharm Biomed Anal
Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]2021 Feb 20:195:113870. PMID: 33453569 -
Breast Cancer Res Treat
Monopolar spindle 1 contributes to tamoxifen resistance in breast cancer through phosphorylation of estrogen receptor α. [Abstract]2023 Dec;202(3):595-606. PMID: 37695401 -
Chin J Integr Med
Curcumin Inhibits Fibroblast Differentiation and Epithelial-Mesenchymal Transition to Alleviate Adenomyosis through TGF-β1/Smad3 Pathway. [Abstract]2026 Jan 15. PMID: 41540162 -
Oral Dis
DDX5 Alleviates Temporomandibular Joint Osteoarthritis via TNF-Induced NF-κB Signaling Pathway. [Abstract]2025 Jul;31(7):2229-2242. PMID: 40013619 -
J Steroid Biochem Mol Biol
OBHSA, a novel selective estrogen receptor degrader, overcomes tamoxifen resistance through cell cycle arrest and unfolded protein response-mediated apoptosis in breast cancer. [Abstract]2024 Nov:244:106599. PMID: 39147211 -
Hear Res
Chromatin and genomic instability in the cochlea contributing to age-related hearing loss: Insights from in vitro and in vivo models. [Abstract]2026 Aug:478:109691. PMID: 42263393 -
Front Genet
Genome-wide analysis of the FOXA1 transcriptional regulatory network identifies super enhancer associated LncRNAs in tamoxifen resistance. [Abstract]2022 Sep 20:13:992444. PMID: 36204307 -
Biochim Biophys Acta Gen Subj
MFN2-mediated mitochondrial fusion facilitates acute hypobaric hypoxia-induced cardiac dysfunction by increasing glucose catabolism and ROS production. [Abstract]2023 Sep;1867(9):130413. PMID: 37331409 -
Toxicol Res (Camb)
Tamoxifen induced hepatic steatosis in high-fat feeding rats through SIRT1-Foxo1 suppression and LXR-SREBP1c activation. [Abstract]2022 Jul 22;11(4):673-682. PMID: 36051666 -
PLoS One
Response Gene to Complement 32 promotes cell proliferation and tamoxifen resistance in breast cancer via elevated FoxM1 expression. [Abstract]2025 Jul 28;20(7):e0328698. PMID: 40720499 -
Biochem Biophys Res Commun
Tamoxifen promotes myogenic differentiation and skeletal muscle regeneration via activation of the GRP94. [Abstract]2026 Aug 20:827:154022. PMID: 42208231 -
Biochem Biophys Res Commun
SHED aggregation-released extracellular vesicles rejuvenate Gli1+ cells and improve diabetic wound healing. [Abstract]2025 Sep 1:777:152327. PMID: 40651366 -
Biochem Biophys Res Commun
Neutrophils suppress osteogenic differentiation of Gli1+ stem cells via neutrophil extracellular traps and contribute to bone loss in periodontitis. [Abstract]2024 Dec 10:737:150916. PMID: 39489114 -
J Chromatogr B Analyt Technol Biomed Life Sci
Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. [Abstract]2024 Apr 15:1237:124100. PMID: 38547701 -
Biochem Biophys Res Commun
Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. [Abstract]2020 Feb 19;522(4):862-868. PMID: 31806372 -
Pharmacol Biochem Behav
Intranasal LAG3 antibody infusion induces microglia-dependent antidepressant effect by mobilizing astrocytic P2Y1R-mediated BDNF synthesis in the hippocampus. [Abstract]2025 Dec:257:174114. PMID: 41106438 -
Oncol Lett
Functional analysis of the effects of propofol on tamoxifen‑resistant breast cancer cells: Insights into transcriptional regulation. [Abstract]2025 Feb 21;29(4):194. PMID: 40041408 -
Am J Transl Res
Evaluation of the safety and tolerability of tamoxifen for ischemia-incited renal injury in mice. [Abstract]2018 Jul 15;10(7):2184-2194. PMID: 30093955 -
-
-
-
-
-
-
-
-
bioRxiv
Restoration of Spermatogenesis is Dependent on Activation of a SPRY4-ERK Checkpoint Following Germline Stem Cell Damage. [Abstract]2025 Oct 14:2025.10.12.681919. PMID: 41279276 -
bioRxiv
Controlled Delivery of a Neurotrophic Factor in the Adult Mouse Brain Using Engineered Microglia. [Abstract]2025 Oct 7:2025.10.06.680702. PMID: 41279766 -
Cureus
Hsa-miR-181a-5p Enhances the Chemosensitivity of Breast Cancer Cells to Tamoxifen by Regulation of the OSBPL3/RAS Signaling Pathway. [Abstract]2025 Oct 20;17(10):e94996. PMID: 41267704 -
-
-
-
-
-
-
-
Heliyon
Citrus polymethoxyflavones degrade estrogen receptor-alpha (ERα) and combine with tamoxifen for the treatment of estrogen receptor-positive breast cancer. [Abstract]2024 Jun 14;10(12):e33104. PMID: 39022050 -
-
-
-
-
-
-
-
bioRxiv
2023 Mar 15:2023.03.14.532677. PMID: 36993187 -
-
-
-
-
-
-
Res Sq
Sex differences in viral entry protein expression, host responses to SARS-CoV-2, and in vitro responses to sex steroid hormone treatment in COVID-19. [Abstract]2020 Dec 31:rs.3.rs-100914. PMID: 33173861 -
-
Chemosphere
2020 Jan:239:124705. PMID: 31479913
Solvente y solubilidad
DMSO : 50 mg/mL (88.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 10 mg/mL (17.74 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocolo
Mice[3]
Seven-week old TmcsMed1-/- mice and the wild-type littermates are then administered Tamoxifen intraperitoneally at a daily dose of 65 mg/kg body weight for 5 days and then killed at selected intervals after initiation of Tamoxifen treatment. For each experiment 3 to 5 mice for control and csMed1-/- are used. To obtain survival curve 41 csMed1-/- and 41 csMed1fl/fl mice are used. Thirteen TmcsMed-/- mice and the same number of littermates are used for the survival curve experiments using Tamoxifen inducible model.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (296 KB)
-
SDS (701 KB)
- English - EN (701 KB)
- Français - FR (701 KB)
- Deutsch - DE (701 KB)
- Norwegian - NO (701 KB)
- Español - ES (701 KB)
- Swedish - SV (701 KB)
- Italian - IT (701 KB)
- Korean - KR (701 KB)
- Portuguese - PT (701 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18. [Content Brief]
[2]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. [Content Brief]
[3]. Jia Y, et al. Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal DilatedCardiomyopathy in Mice. PLoS One. 2016 Aug 22;11(8):e0160755. [Content Brief]
[4]. Zhao R, et al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 1;5(4):e9934. [Content Brief]
[5]. Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4. [Content Brief]
[6]. Feil S, et, al. Inducible Cre mice. Methods Mol Biol. 2009;530:343-63. [Content Brief]
[7]. Bi Q, et al. Microglia-derived PDGFB promotes neuronal potassium currents to suppress basal sympathetic tonicity and limit hypertension. Immunity. 2022 Aug 9;55(8):1466-1482.e9. [Content Brief]
[8]. Chen MY, et al. A review of tamoxifen administration regimen optimization for Cre/loxp system in mouse bone study. Biomed Pharmacother. 2023 Sep;165:115045. [Content Brief]
[9]. El-Beshbishy HA. Hepatoprotective effect of green tea (Camellia sinensis) extract against tamoxifen-induced liver injury in rats. J Biochem Mol Biol. 2005 Sep 30;38(5):563-70. [Content Brief]
[10]. El-Beshbishy H A. The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective[J]. BMB Reports, 2005, 38(3): 300-306. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 1.7742 mL | 8.8709 mL | 17.7418 mL | 44.3546 mL |
| 5 mM | 0.3548 mL | 1.7742 mL | 3.5484 mL | 8.8709 mL | |
| 10 mM | 0.1774 mL | 0.8871 mL | 1.7742 mL | 4.4355 mL | |
| 15 mM | 0.1183 mL | 0.5914 mL | 1.1828 mL | 2.9570 mL | |
| DMSO | 20 mM | 0.0887 mL | 0.4435 mL | 0.8871 mL | 2.2177 mL |
| 25 mM | 0.0710 mL | 0.3548 mL | 0.7097 mL | 1.7742 mL | |
| 30 mM | 0.0591 mL | 0.2957 mL | 0.5914 mL | 1.4785 mL | |
| 40 mM | 0.0444 mL | 0.2218 mL | 0.4435 mL | 1.1089 mL | |
| 50 mM | 0.0355 mL | 0.1774 mL | 0.3548 mL | 0.8871 mL | |
| 60 mM | 0.0296 mL | 0.1478 mL | 0.2957 mL | 0.7392 mL | |
| 80 mM | 0.0222 mL | 0.1109 mL | 0.2218 mL | 0.5544 mL |